{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"NCT05700461","nct_id":"NCT05700461","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct05700461. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants with confirmed or suspected metastatic Renal Cell Carcinoma (RCC) and who are candidates for standard of care metastatectomy or debulking/consolidative nephrectomy will be selected for study participation and will undergo study procedures as outlined:\n\n* Placement of 1-6 microdevice(s) 72 +/- 24 hours prior to scheduled, standard of care surgery. The number of microdevices implanted into a tumor will be made on a case-by-case basis based on tumor and participant factors before and during the procedure.\n* At the time of standard of care surgery, surgical removal of microdevice(s) along with surrounding tumor tissue.\n* Monitoring for safety endpoints during inpatient stay and at a follow-up clinic visit.","label":"Implantable microdevice (IMD) + Biopsy + Standard of Care Treatment","type":"EXPERIMENTAL"}],"collaborators":["Dana-Farber Cancer Institute"],"completion_date":{"date":"2029-08-31","type":"ESTIMATED"},"conditions":["Renal Cell Carcinoma","Metastatic Renal Cell Carcinoma","Kidney Cancer"],"enrollment":{"count":20,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Implantable Microdevice (IMD)","otherNames":[],"type":"COMBINATION_PRODUCT"}],"last_update":"2026-05-18","lead_sponsor":"Oliver Jonas","official_title":"Pilot Study of an Implantable Microdevice for in Situ Evaluation of Drug Response in Renal Cell Carcinoma","overall_status":"RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2028-10-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Safety of microdevice implantation","timeFrame":"Up to 30 days"},{"measure":"Number of Patients with Feasible Microdevice Procedure","timeFrame":"72 hours"}],"references":[],"start_date":{"date":"2024-12-01","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Drug Screening Using Novel IMD in Renal Cell Carcinoma","url":"https://clinicaltrials.gov/study/NCT05700461"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct05700461"}